AstraZeneca partners with insitro on AI-driven cardiometabolic drug discovery
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
Tweet
Share
E-mail
Get Alerts AZN Hot Sheet
Join SI Premium – FREE
AstraZeneca (NASDAQ: AZN) has entered into a drug discovery collaboration and licensing agreement with insitro, an artificial intelligence therapeutics company, according to a company statement dated October 15, 2026.
The collaboration will use AI systems to identify drug targets and develop therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) and cardiomyopathies.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bank of America adds two former CEOs to its board
- VS MEDIA Holdings renamed Forcendra, ticker to change to FCDH
- N-able and SentinelOne expand cybersecurity partnership
Create E-mail Alert Related Categories
Corporate News, Hot Corp. NewsRelated Entities
Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
